title: Systemic CD56+ cells can predict pregnancy outcome.
abstract: OBJECTIVE
  To evaluate differences in circulating CD56+ cells between successful and unsuccessful pregnancies, 114 pregnant women were studied prospectively.
  
  
  METHODS
  Seventy women had a history of infertility (INF) and 44 had two or more previous spontaneous abortions (RSA). Among the infertile women, 12 were donor egg recipients (DER) and 15 underwent intracytoplasmic sperm injection (ICSI) for treatment of male factor infertility. Nineteen women were carrying multiple gestations (MG) and 55 had singleton gestations (SG). Thirteen additional women were receiving intravenous immunoglobulin (IVIg).
  
  
  RESULTS
  The percentage of CD56+ cells was determined in 310 blood samples from 114 pregnant women by flow cytometry. The prevalence of women with persistent elevation of percent of 56+ cells (> 12%) was 58% among DER, 73% among ICSI, 37% among MG, 22% among SG, 18% among RSA, and 39% among INF. Thirteen women with SG received IVIG, 10 had CD56+ cells greater than 12% and all 13 experienced live births. Women with percentage CD56+ cells persistently greater than 12% who were not DER, not ICSI, not receiving IVIg, and not carrying MG had a live birth rate of 11%. Women with greater than 12% CD56+ cells had normal karyotype in 78% of concepti studied in contrast to women less than 12% CD56+ cells who had 68% abnormal karyotypes (P = 0.04).
  
  
  CONCLUSIONS
  Elevated CD56+ cells in pregnant women who are not DER, not ICSI, not receiving IVIg, and not carrying MG predicts loss of a karyotypically normal conceptus with a specificity of 87% and positive predictive value of 78%. While the specificity value of this test is high in both infertile and RSA populations, the sensitivity is 86% in RSA and only 54% in INF suggesting this test does not identify all losses among INF. It may identify a subset of pregnancies at risk for loss of a karyotypically normal embryo that may respond to treatment with IVIg.
authors.affiliation: Genetics & IVF Institute, Fairfax, Virginia 30231, USA.
authors.forename: C B
authors.initials: CB
authors.lastname: Coulam
authors.forename: C
authors.initials: C
authors.lastname: Goodman
authors.forename: R G
authors.initials: RG
authors.lastname: Roussev
authors.forename: E J
authors.initials: EJ
authors.lastname: Thomason
authors.forename: K D
authors.initials: KD
authors.lastname: Beaman
mesh_terms: D000026:Abortion, Habitual / Q000453:epidemiology; D000328:Adult; D015703:Antigens, CD / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D019002:CD56 Antigen; D015897:Comorbidity; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007247:Infertility, Female / Q000453:epidemiology; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets; D011237:Predictive Value of Tests; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology; D011272:Pregnancy, Multiple; D011446:Prospective Studies; D017584:Reproductive History; D012680:Sensitivity and Specificity
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019002:CD56 Antigen; D016756:Immunoglobulins, Intravenous